## Maidstone and **NHS** Tunbridge Wells

Ref: FOI/GS/ID 4381

.....

## Please reply to:

FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone Kent ME16 9QQ Email: mtw-tr.foiadmin@nhs.net

31 January 2018

## Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Extravasation Incidents.

Name of person completing request: Hospital Trust/Health Board: Telephone No: E-mail Address: 1. Does your organisation provide a chemotherapy service – this may include inpatient, outpatient or a community service? 0 Yes 0 No

2. In the past financial year, how many doses of chemotherapy did you deliver? (April 2016 – March 2017)

3. In the past financial year, how many doses of anthracyclines did you administer? (April 2016 – March 2017)

4. In the past financial year, how many anthracycline extravasations have been reported due to chemotherapy? (April 2016 – March 2017)

5. In the past 3 financial years, how many patients have submitted a claim for medical negligence and/or damages against the Trust/Health Board due to an anthracycline extravasation injury?

6. In the past 3 financial years, how much compensation has the Trust/Health Board had to pay to those claimants who have suffered an anthracycline extravasation injury and have been successful in their medical negligence and/or damages case?

7. Does your Trust/Health Board have in place guidelines as to how to recognise and manage an extravasation injury? If not, is this available via your Cancer Alliance/Network or another source? If other, please state source

Chairman: David Highton Chief Executive: Miles Scott Trust Headquarters: Maidstone Hospital, Hermitage Lane, Maidstone, Kent ME16 9QQ Telephone: 01622 729000 / 01892 823535 Trust/Health Board Guidelines 0 Yes 0 NoIf yes, when were theylast updated?.....

8. Does your Trust/Health Board stock or have readily available any of the following extravasation treatments for chemotherapy?
a. Sodium Thiosulfate 0 Yes 0 No If yes, how often used in the past financial year? (April 2016 – March 2017)......
b. Hyaluronidase 0 Yes 0 No If yes, how often used in the past financial year? (April 2016 – March 2017).....
c. DMSO 0 Yes 0 No If yes, how often used in the past financial year? (April 2016 – March 2017).....
d. Dexrazoxane (Savene) 0 Yes 0 No If yes, how often used in the past financial year? (April 2016 – March 2017).....

9. In the past 3 financial years, how many annual reconstruction operations have been carried out by the Trust/Health Board due to an extravasation injury?

10. Does your Trust/Health Board's plastics and/or nursing team have the expertise/core competency to undertake the wash-out/flush-out technique if an extravasation occurs? 0 Yes 0 No

11. If you answered yes to question 10, in the past 3 financial years, how many wash-out/flush-out procedures have been carried out by the Trust/Health Board due to an extravasation incident?

Name of person completing request:	**					
Hospital Trust/Health Board:	Maidstone and Tunbridge Wells NHS Trust					
Telephone No: **						
E-mail Address: **						
1. Does your organisation provide a chemotherapy service – this may include inpatient, outpatient or a community service? x Yes 🗌 No						
2. In the past financial year, how mar deliver? (April 2016 – March 2017		20041				
<ol> <li>In the past financial year, how many doses of anthracyclines did you administer? (April 2016 – March 2017)</li> </ol>		961				
<ol> <li>In the past financial year, how many anthracycline extravasations have been reported due to chemotherapy? (April 2016 – March 2017)</li> </ol>		One				
5. In the past 3 financial years, how r	In the past 3 financial years, how many patients have submitted a claim for medical negligence and/or damages against the Trust/Health Board due to an anthracycline extravasation injury?		2015-2016	2016 -2017		
			0	0		
6. In the past 3 financial years, how r	much compensation has the	2014-2015	2015-2016	2016 -2017		
Trust/Health Board had to pay to those claimants who have suffered an anthracycline extravasation injury and have been successful in their medical negligence and/or damages case?		0	0	0		
7. Does your Trust/Health Board have in place guidelines as to how to recognise and manage an extravasation injury? If not, is this available via your Cancer Alliance/Network or another source? If other, please state source. We have trust policy which is the same as our Kent and Medway Cancer Collaborative guidelines						

	Trust/Health Board Guidelines x Yes	No If yes, when w	ere they last updated?	September 2016				
8. Does your Trust/Health Board stock or have readily available any of the following extravasation treatments for chemotherapy?								
	a. Sodium Thiosulfate	Yes x No If yes,	Yes x No If yes, how often used in the past financial year? (April 2016 – March 2017)					
	b. Hyaluronidase	x Yes 🗌 No If yes, how often used in the past financial year? (April 2016 – March 2017)						
	c. DMSO	x Yes 🗌 No 🛛 If yes,	x Yes 🗌 No 🛛 If yes, how often used in the past financial year? (April 2016 – March 2017)					
	d. Dexrazoxane (Savene) x Yes 🗌 No If yes, how often used in the past financial year? (April 2016 – March 2017)							
9. In the past 3 financial years, how many annual reconstruction operations have been carried out by the Trust/Health Board due to an extravasation injury?			2014-2015	2015-2016	2016 -2017			
			0	0	0			
10. Does your Trust/Health Board's plastics and/or nursing team have the expertise/core competency to undertake the wash-out/flush-out technique if an extravasation occurs?								
Yes x No								
11. If you answered yes to question 10, in the past 3 financial years,			2014-2015	2015-2016	2016 -2017			
how many wash-out/flush-out procedures have been carried out by the Trust/Health Board due to an extravasation incident?		n/a	n/a	n/a				

Chairman: David Highton Chief Executive: Miles Scott Trust Headquarters: Maidstone Hospital, Hermitage Lane, Maidstone, Kent ME16 9QQ Telephone: 01622 729000 / 01892 823535